Secondary Leukemia: Research Suggests New Ways to Understand What Causes This Side Effect of Cancer Treatment

Rack of blood vials
Summary

MSK investigators have found that the presence of certain gene mutations in patients’ blood may mean they are more likely to get a secondary leukemia. The discovery may lead to new methods for determining who is at greatest risk.

One of the most devastating things that can happen to a person who has survived cancer is later being diagnosed with treatment-related leukemia. This problem is becoming more common as more people are being cured of their disease and survivors are living longer.

Secondary leukemia arises because some treatments for cancer — such as radiation therapy and certain types of chemotherapy — can damage the DNA and lead to mutations. The risk of developing the disease varies greatly, depending on the original cancer and which treatments were given. It can range from less than 0.1% to as high as 3 or 4% in the ten years after treatment.

Now a team of researchers from Memorial Sloan Kettering is reporting that they have identified the presence of certain genetic mutations in the blood that indicate someone is more likely to develop a secondary leukemia. In addition, these mutations are linked to a decreased likelihood that the patient will survive the original cancer, regardless of where the tumor formed in the body.

The findings, which are reported in Cell Stem Cell, came about thanks to MSK-IMPACT™, a test that looks for gene mutations in a patient’s tumor and may guide the choice of therapy.

“MSK-IMPACT compares DNA from a patient’s tumor and from noncancerous blood cells to identify tumor-specific mutations that might be targeted with drugs. From the time we started MSK-IMPACT testing in 2014, we noticed that some patients had acquired cancer-related genetic mutations in their blood that weren’t in the tumors,” says Michael Berger, an Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and one of the researchers who developed the test. “Not only were these mutations in the blood but they were known to be associated with leukemia. We decided to talk to Ross Levine about what this might mean.”

A Collaboration Leads to Answers

Dr. Levine, a physician-scientist in MSK’s Human Oncology and Pathogenesis Program and Director of the Center for Hematologic Malignancies, focuses on studying genes that play a role in blood cancers, such as leukemia. In addition, he was one of the first researchers to report on a phenomenon called clonal hematopoiesis (CH).

We need to do more research to understand how different mutations impact the risk of leukemia and to develop clinical tools to be able to predict who is at risk.
Ross L. Levine
Ross L. Levine physician-scientist

CH occurs when hematopoietic stem cells — the cells that give rise to all types of blood cells — form a subpopulation of cells that is genetically distinct from the rest of the blood stem cells. In the current study, the researchers found that 25% of cancer patients had CH, a higher number than had previously been observed, and that 4.5% of them carried mutations known to drive the formation of leukemia.

Back to top Arrow (up) icon.Icon pointing upwards. Usually means that the containing element can be opened and closed.

Assessing the Risk

“It’s exciting to us because it suggests this is a common phenomenon, and one that we need to understand more,” Dr. Levine says. “Only a small subset of patients with these mutations subsequently develop leukemia, so we need to do more research to understand how different mutations impact the risk of leukemia and to develop clinical tools to be able to predict who is at risk.”

CH is not unique to people with cancer — it may arise in people who are completely healthy. Previous studies have shown that the older people get, the more likely they are to have these genetically unique subpopulations of cells in their blood. This makes sense because leukemia is more common in older people.

“These findings don’t give us any definitive answers, but they point to a direction where we can begin to ask new questions,” Dr. Levine adds. “This type of research brings together researchers with many different areas of expertise, and it’s the collaborative nature of MSK that made it possible.”

Back to top Arrow (up) icon.Icon pointing upwards. Usually means that the containing element can be opened and closed.

The co-first authors of the study are Catherine Coombs, a former medical oncology fellow who is now at the University of North Carolina, Chapel Hill, and Ahmet Zehir, Director of Clinical Bioinformatics in MSK’s Molecular Diagnostics Service. This research was supported by the National Institutes of Health and the National Cancer Institute (P30 CA008748), the Conquer Cancer Foundation, an American Society of Clinical Oncology Young Investigator Award, a Stand Up To Cancer Convergence Grant, the V Foundation for Cancer Research, and the National Science Foundation.

Comments

Very nice blog ,keep on posting

Was recently told of this diagnosis. Probably result of too ,amy cortisone injections. Need help to find cre here as well as in Orlando, Fla. Should be moving in short period of time. Is warmer weather aggravating to this condition. Any and all info will be appreciated. Thank you.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.